An increase in serum NfL was confirmed to be associated with disease progression 1 year after serum sampling in patients with CIDP but has not been shown to reflect short‐term treatment responses after IVIg administration [33, 34, 35]. This evidence concerns the gene NEFL and chronic inflammatory demyelinating polyradiculoneuropathy.